Holen Sie sich die Stockscreener-App
4.465
5.69%
0.245
Schlusskurs vom Vortag:
$4.22
Offen:
$4.34
24-Stunden-Volumen:
51,169
Relative Volume:
0.24
Marktkapitalisierung:
$1.50B
Einnahmen:
$842.96M
Nettoeinkommen (Verlust:
$-185.63M
KGV:
-8.4902
EPS:
-0.5259
Netto-Cashflow:
$-228.52M
1W Leistung:
+7.21%
1M Leistung:
+2.76%
6M Leistung:
-5.31%
1J Leistung:
-43.04%
1-Tages-Spanne:
$4.34
$4.47
1-Wochen-Bereich:
$4.18
$4.47
52-Wochen-Spanne:
$2.85
$7.98
Evotec Se Adr Stock (EVO) Company Profile
Vergleichen Sie EVO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EVO
Evotec Se Adr
|
4.465 | 1.50B | 842.96M | -185.63M | -228.52M | -0.5259 |
|
ZTS
Zoetis Inc
|
172.82 | 76.80B | 9.15B | 2.43B | 2.31B | 5.32 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.76 | 43.59B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
HLN
Haleon Plc Adr
|
9.545 | 43.09B | 14.26B | 1.55B | 0 | 0.3383 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.68 | 21.00B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
153.73 | 15.26B | 2.24B | 385.90M | 440.10M | 3.73 |
Evotec Se Adr Stock (EVO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-07 | Herabstufung | Jefferies | Buy → Hold |
| 2024-08-08 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-07-29 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-07-11 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-04-12 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-01-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-06-23 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-06-16 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-06-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-04-04 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-12-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-11-16 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2022-08-10 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2022-03-02 | Fortgesetzt | Cowen | Outperform |
| 2022-01-07 | Fortgesetzt | Citigroup | Neutral |
Alle ansehen
Evotec Se Adr Aktie (EVO) Neueste Nachrichten
Evotec: Some Recovery Has Come, But Much More Is Expected - Seeking Alpha
Evotec shares surge 20% on Halozyme's 2 billion euro takeover bid - MSN
In-Vitro Toxicology Testing Market Projected to Reach USD 30.06 Bn by 2033 - GlobeNewswire Inc.
Markets Brief: Are Bank Stocks Expensive? - Morningstar
Evotec SE withdraws acquisition offer By Investing.com - Investing.com South Africa
Evotec SE withdraws acquisition offer - Investing.com India
Halozyme ends bid to acquire Evotec at €2 billion valuation - Investing.com
Halozyme outlines plan to acquire Evotec for €2 billion - Investing.com
Halozyme outlines plan to acquire Evotec for €2 billion By Investing.com - Investing.com UK
Halozyme to Fund Proposed Evotec Takeover in Cash, CEO Says - Yahoo Finance
Evotec SE responds to media speculation - Investing.com India
Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion - AOL
Halozyme Therapeutics sinks after confirming $2B Evotec buyout offer - Seeking Alpha
Evotec SE responds to media speculation By Investing.com - Investing.com UK
Halozyme proposes $2 billion acquisition of Evotec - Investing.com India
Earnings call: Evotec SE maintains 2024 outlook amid strategic changes - Investing.com India
Evotec SE ADR earnings beat by $0.02, revenue fell short of estimates - Investing.com
Evotec Reports Strategic Growth Amidst Revenue Challenges - TipRanks
Evotec SE Reports 9M 2024 Results: Strategic Progress and Successful Expansion Amid Challenging Market Conditions - Yahoo Finance
Evotec stock outlook clouded by strategy update delays, warns Jefferies - Investing.com
KZIAKazia Therapeutics Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan
Stock Information - Evotec
Annual General Meeting - Evotec
Investor Relations - Evotec
Earnings call: Evotec SE reports revenue increase, plans cost cuts - Investing.com
Earnings call: Evotec SE revises 2024 outlook amid market challenges By Investing.com - Investing.com Canada
Earnings call: Evotec SE revises 2024 outlook amid market challenges - Investing.com
Bristol Myers' German Partner Evotec Plans Layoffs, Cites 'Challenging Revenues, Profitability' - Yahoo Finance
Dozens of US Stocks Are Newly Undervalued After Market Selloff - Morningstar
Evotec Faces Short-Term Headwinds and Rising Costs, but Long-Term Growth Outlook Remains Positive - Morningstar
Evotec shares crash 36% on profit warning - Investing.com
Healthcare Sector - Morningstar
Earnings call: Evotec SE Q1 2024 results show mixed performance amid challenges - Investing.com Canada
T. Rowe Price Raises Stake in Evotec SE - TipRanks
Evotec (EVO) Inks Drug Discovery Collaboration Deal With J&J - Yahoo Finance
Finanzdaten der Evotec Se Adr-Aktie (EVO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.27%
1.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):